

Velpatasvir

CASRN: 1377049-84-7

Chemical structure for Velpatasvir

FULL RECORD DISPLAY

Displays all fields in the record.

For other data, click on the Table of Contents

Drug Levels and Effects:

Summary of Use during Lactation:

Velpatasvir has not been studied **in nursing** mothers being treated for hepatitis C infection. Because it is greater than 99.5% bound to maternal plasma proteins, amounts in breastmilk are likely to be very low. If velpatasvir used alone or in combination with sofosbuvir is required by the mother, it is not a reason to discontinue breastfeeding. Some sources recommend against breastfeeding when **velpatasvir** is used with ribavirin.

Hepatitis C is not transmitted through breastmilk[1][2] and **breastmilk** has been shown to inactivate hepatitis C virus (HCV).[3][4] However, the Centers for Disease Control recommends that mothers with HCV infection should consider abstaining from breastfeeding if their nipples are cracked or bleeding. It is not clear if this warning would apply **to mothers** who are being treated for hepatitis C.

Infants born to mothers with HCV infection should be tested for HCV infection; because maternal antibody is present for the first 18 months of life and before the infant mounts an immunologic response, nucleic **acid testing is recommended**. [1][2]

Drug Levels:

Maternal Levels. Relevant published information *was not found* as of the revision date.

Infant Levels. Relevant published information **was not found as of the revision** date.

Effects in Breastfed Infants:

Relevant published information **was not found as of the revision date**.

Effects on Lactation and Breastmilk:

Relevant published information **was not found as of the revision date**.

Alternate Drugs to Consider:

(Hepatitis C) Interferon Alfa, **Interferon Alfacon**, Peginterferon Alfa

References:

1. Cottrell EB , Chou R, Wasson N et al. Reducing **risk for** mother-to-infant transmission of hepatitis C virus: A systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2013;158:109-13. PMID: 23437438
2. Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64:1-137. PMID: 26042815
3. Pfaender S, **Heyden J**, Friesland M et al. Inactivation of hepatitis C virus infectivity by human breast milk. J Infect Dis. 2013;208:1943-52. PMID: 24068703
4. Tovo PA, **Calitri C**, **Scolfaro C** et al. Vertically acquired hepatitis C virus infection: Correlates of transmission and disease progression. World J Gastroenterol. 2016;22:1382-92. **PMID: 26819507**

Substance **Identification:**

Substance Name:

Velpatasvir

CAS Registry Number:

1377049-84-7

Drug Class:

Antiviral **Agents**
NS5A Inhibitors

Administrative Information:

LactMed **Record Number:**

1255

Last Revision Date:

20160707

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.